ForNRG1/2gene fusion solid tumors, if standard treatment fails, it is recommended to participation in related clinical trials for pan-ERBB TKIs such as afatinib and tarloxotinib, or ERBB2 inhibitory mAbs, ERBB3 inhibitory mAbs or dual anti-ERBB2/ERBB3 mAbs such as zenocutuzumab. ForNRG1/2gene fusion tumor patients with drug resistance, performing NGS test to identify resistance mechanisms and deciding whether other related clinical trials are appropriate is recommended. Here, ERBB3 is linked to neoplasm.